Grants per year
Grants
- 36 Finished
- 1 - 25 out of 36 results
Search results
-
Finished
Prot #GS-US-436-4092: A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety and Efficacy of Filgotinib and GS-9876 in Female Subjects with Moderately-to-Severely Active Cutaneous Lupus Erythematosus (CLE)
Laumann, A. E. (PD/PI)
ICON Clinical Research, L.P., Gilead Sciences, Inc
7/27/17 → 7/27/20
Project: Research project
-
Prot #8400-211: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial of IMO-8400 In Patients with Dermatomyositis
Laumann, A. E. (PD/PI)
Parexel, Idera Pharmaceuticals, Inc.
3/14/16 → 3/14/19
Project: Research project
-
Prot #CC-220-SLE-001: A PILOT, PHASE 2, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND, STUDY TO EVALUATE EFFICACY, SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS AND PHARMACOGENETICS OF CC-220 IN SUBJECTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS
Laumann, A. E. (PD/PI)
PPD Development, Celgene Corporation
4/7/15 → 4/7/19
Project: Research project
-
Prot #X052172: A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Gevokizumab in Treating Active Ulcers of Pyoderma Gangrenosum
Laumann, A. E. (PD/PI)
Clinipace, Inc., XOMA (US) LLC
3/19/15 → 3/19/18
Project: Research project
-
Prot #X052171: A 2-Year, Open-Label, Safety Extension Study of Gevokizumab in Patients with Pyoderma Gangrenosum
Laumann, A. E. (PD/PI)
Therapeutics, Inc., XOMA (US) LLC
3/19/15 → 3/19/18
Project: Research project
-
Prot #R668-AD-1225: An Open-Label Study of Dupilumab in Patients with Atopic Dermatitis Who Participated in Previous Dupilumab Clinical Trials
Laumann, A. E. (PD/PI)
Parexel, Regeneron Pharmaceuticals, Inc.
5/5/14 → 5/5/20
Project: Research project
-
Clinical and molecular Characterization of lichen Sclerosus as a Model of Vulvar Epithelial Fibrosis
Schlosser, B. J. (PD/PI) & Laumann, A. E. (Other)
7/1/12 → 6/30/15
Project: Research project
-
Prot# CNTO1959PSO2001: A Phase 2 Multicenter, Randomized, Placebo- and Active-Comparator-Controlled, Dose-Ranging Trial to Evaluate CNTO 1959 for the Treatment of Subjects with Moderate to Severe Plaque-type Psoriasis (X-PLORE)
Gordon, K. B. (PD/PI), Laumann, A. E. (Co-PD/PI) & West, D. P. (Co-PD/PI)
Parexel, Janssen Research & Development, LLC
5/4/12 → 5/4/15
Project: Research project
-
Prot# I1F-MC-RHAZ: A Multicenter Study with a Randomized, Double-Blind, Placebo-Controlled Induction Dosing Period Followed by a Randomized Maintenance Dosing Period and a Long-Term Extension Period to Evaluate the Efficacy and Safety of LY2439821 in Pati
Amin, A. Z. (PD/PI) & Laumann, A. E. (Co-PD/PI)
Parexel, Eli Lilly and Company
4/30/12 → 11/30/19
Project: Research project
-
Prot#A6261008: A Randomized, Subject and Investigator-Blinded (Sponsor-Open), Placebo-Controlled Dose Escalation Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Multiple Doses of PD 0360324 in Subjects with Active Cutaneous Lupus E
Laumann, A. E. (PD/PI)
10/21/11 → 10/21/14
Project: Research project
-
Prot# CC-10004-PSOR-009: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Apremilast (CC-10004) in Subjects with Moderate to Severe Plaque Psoriasis
Laumann, A. E. (PD/PI) & Singri, P. (Co-PD/PI)
INC Research, LLC, Celgene Corporation
7/14/11 → 7/14/17
Project: Research project
-
Prot#R668-AD-0914: A Randomized, Double-Blind, Placebo-Controlled, Sequential Ascending, Repeated-Dose Study of the Safety and Pharmacokinetics of Subcutaneous REGN668 in Patients with Moderate-to-Severe Extrinsic Atopic Dermatitis
Laumann, A. E. (PD/PI), Paller, A. (Co-PD/PI) & West, D. P. (Co-PD/PI)
Ingenix Pharmaceutical Services, Inc., Regeneron Pharmaceuticals, Inc.
2/1/11 → 2/1/14
Project: Research project
-
Prot# CC-11050-CLE-002: A Phase 2, Pilot, Multicenter, Sequential, Ascending Dose Study to Evaluate the Preliminary Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of CC-11050 in Subjects with Discoid Lupus Erythematosus and Subacut
Laumann, A. E. (PD/PI) & West, D. P. (Co-PD/PI)
12/8/10 → 12/8/13
Project: Research project
-
PROT# MEL-041509: Phase II Randomized, Double-Blind, Placebo-Controlled, Three-Arm,Dose-Finding, Study to Evaluate the Safety and Efficacy of Erlotinib in the Treatment of Moderate to Severe Psoriasis
Laumann, A. E. (PD/PI), Singri, P. (Co-PD/PI) & West, D. P. (Co-PD/PI)
10/7/09 → 10/7/12
Project: Research project
-
Development and Translational Assessment of a Tongue-Based Assistive Neuro-Technology for Individuals with Severe Neurological Disorders
Laumann, A. E. (PD/PI) & West, D. P. (Co-Investigator)
Georgia Institute of Technology, National Institute of Biomedical Imaging and Bioengineering
9/30/09 → 8/31/12
Project: Research project
-
Prot# BAP01346: Efficacy and Safety of Alitretinoin in the Treatment of Severe Chronic Hand Eczema Refractory to Topical Therapy
Laumann, A. E. (PD/PI), Dago, P. L. (Co-PD/PI), Martini, M. C. (Co-PD/PI) & West, D. P. (Co-PD/PI)
Covance Periapproval Services, Inc., Basilea Pharmaceutica International Ltd.
5/26/09 → 5/26/12
Project: Research project
-
Prot# P10-023: A 10-Year, Post-Marketing, Observational, Registry of HUMIRA (Adalimumab) in Adult Patients With Chronic Plaque Psoriasis (Ps)
Amin, A. Z. (PD/PI), West, D. P. (Co-PD/PI) & Laumann, A. E. (Other)
United BioSource LLC, Abbott Laboratories
4/20/09 → 12/31/21
Project: Research project
-
Prot #C0168Z03: A Multicenter, Open Registry of Patients with Psoriasis Who are Candidates for Systemic Therapy Includes Biologics
Amin, A. Z. (PD/PI), Paller, A. (Co-PD/PI), Singri, P. (Co-PD/PI), West, D. P. (Co-PD/PI) & Laumann, A. E. (Other)
Mapi USA, Inc., Janssen Biotech, Inc.
3/2/09 → 3/2/21
Project: Research project
-
Tadalafil for the Treatment of Secondary Raynaud's Phenomenon
Laumann, A. E. (PD/PI) & West, D. P. (Co-PD/PI)
5/19/08 → 5/19/11
Project: Research project
-
A Multicenter, Open-Label, Controlled Phase II Study to Evaluate Safety and Immunogenicity of MVA-BN (IMVAMUNE) Smallpox Vaccine in 18-40 Year Old Subjects with Diagnosed Atopic Dermatitis
Laumann, A. E. (PD/PI) & West, D. P. (Co-Investigator)
Bavarian Nordic A/S, National Institute of Allergy and Infectious Diseases
3/1/08 → 2/28/10
Project: Research project
-
A Multicenter, Open-Label, Controlled Phase II Study to Evaluate Safety and Immunogenicity of MVA-BN (IMVAMUNE) Smallpox Vaccine in 18-40 Year Old Subjects with Diagnosed Atopic Dermatitis
Laumann, A. E. (PD/PI) & West, D. P. (Co-Investigator)
Bavarian Nordic A/S, National Institute of Allergy and Infectious Diseases
3/1/08 → 2/28/10
Project: Research project
-
Prot# C-2006-004-03: A Double-Blind, Randomized, Placebo-Controlled, Sequential Cohort Exploratory Study of the Safety and Efficacy of JNJ-26113100 in the Treatment of Adult Atopic Dermatitis that is Moderate in Severity
Laumann, A. E. (PD/PI), Paller, A. (Co-PD/PI) & West, D. P. (Co-PD/PI)
Janssen Research & Development, LLC
4/2/07 → 4/2/08
Project: Research project
-
Prot# C-2006-004-03: A Double-Blind, Randomized, Placebo-Controlled, Sequential Cohort Exploratory Study of the Safety and Efficacy of JNJ-26113100 in the Treatment of Adult Atopic Dermatitis that is Moderate in Severity
Laumann, A. E. (PD/PI), Paller, A. (Co-PD/PI) & West, D. P. (Co-PD/PI)
Janssen Research & Development, LLC
4/2/07 → 4/2/08
Project: Research project